Glomerular diseases最新文献

筛选
英文 中文
A Genetic Risk Score Distinguishes Different Types of Autoantibody-Mediated Membranous Nephropathy. 基因风险评分可区分不同类型的自身抗体介导的膜性肾病
Glomerular diseases Pub Date : 2023-03-13 eCollection Date: 2023-01-01 DOI: 10.1159/000529959
Sanjana Gupta, Mallory Lorraine Downie, Chris Cheshire, Stephanie Dufek-Kamperis, Adam Paul Levine, Paul Brenchley, Elion Hoxha, Rolf Stahl, Neil Ashman, Ruth Jennifer Pepper, Sean Mason, Jill Norman, Detlef Bockenhauer, Horia Constantin Stanescu, Robert Kleta, Daniel Philip Gale
{"title":"A Genetic Risk Score Distinguishes Different Types of Autoantibody-Mediated Membranous Nephropathy.","authors":"Sanjana Gupta, Mallory Lorraine Downie, Chris Cheshire, Stephanie Dufek-Kamperis, Adam Paul Levine, Paul Brenchley, Elion Hoxha, Rolf Stahl, Neil Ashman, Ruth Jennifer Pepper, Sean Mason, Jill Norman, Detlef Bockenhauer, Horia Constantin Stanescu, Robert Kleta, Daniel Philip Gale","doi":"10.1159/000529959","DOIUrl":"10.1159/000529959","url":null,"abstract":"<p><strong>Introduction: </strong>Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults and is characterized by detectable autoantibodies against glomerular antigens, most commonly phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type-1 domain containing 7A (THSD7A). In Europeans, genetic variation in at least five loci, <i>PLA2R1</i>, <i>HLA-DRB1</i>, <i>HLA-DQA1, IRF4, and NFKB1,</i> affects the risk of disease. Here, we investigated the genetic risk differences between different autoantibody states.</p><p><strong>Methods: </strong>1,409 MN individuals were genotyped genome-wide with a dense SNV array. The genetic risk score (GRS) was calculated utilizing the previously identified European MN loci, and results were compared with 4,929 healthy controls and 422 individuals with steroid-sensitive nephrotic syndrome.</p><p><strong>Results: </strong>GRS was calculated in the 759 MN individuals in whom antibody status was known. The GRS for MN was elevated in the anti-PLA2R1 antibody-positive (<i>N</i> = 372) compared with both the unaffected control (<i>N</i> = 4,929) and anti-THSD7A-positive (<i>N</i> = 31) groups (<i>p</i> < 0.0001 for both comparisons), suggesting that this GRS reflects anti-PLA2R1 MN. Among PLA2R1-positive patients, GRS was inversely correlated with age of disease onset (<i>p</i> = 0.009). Further, the GRS in the dual antibody-negative group (<i>N</i> = 355) was intermediate between controls and the PLA2R1-positive group (<i>p</i> < 0.0001).</p><p><strong>Conclusion: </strong>We demonstrate that the genetic risk factors for PLA2R1- and THSD7A-antibody-associated MN are different. A higher GRS is associated with younger age of onset of disease. Further, a proportion of antibody-negative MN cases have an elevated GRS similar to PLA2R1-positive disease. This suggests that in some individuals with negative serology the disease is driven by autoimmunity against PLA2R1.</p>","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"116-125"},"PeriodicalIF":0.0,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9380839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
pSTAT1 Is Activated during the Progression of IgA Nephropathy. pSTAT1在IgA肾病的进展过程中被激活
Glomerular diseases Pub Date : 2023-01-01 DOI: 10.1159/000526056
Jianling Tao, Neeraja Kambham, Shirley Kwok, Richard A Lafayette
{"title":"pSTAT1 Is Activated during the Progression of IgA Nephropathy.","authors":"Jianling Tao,&nbsp;Neeraja Kambham,&nbsp;Shirley Kwok,&nbsp;Richard A Lafayette","doi":"10.1159/000526056","DOIUrl":"https://doi.org/10.1159/000526056","url":null,"abstract":"<p><strong>Introduction: </strong>IgA nephropathy is the most common primary glomerular disease. Its pathogenesis is still poorly understood. Alterations of the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway may play an important role in IgA nephropathy.</p><p><strong>Methods: </strong>We evaluated the clinical features, pathology, and tissue staining for lymphocytes and phosphorylated STAT1 (pSTAT1) in 43 patients with biopsy proven IgA nephropathy. They were followed to determine their disease outcomes. All had biopsy tissue and multiple laboratory measurements to assess their kidney disease progression. Sixteen patients underwent repeat kidney biopsy to further assess their clinical status.</p><p><strong>Results: </strong>The median eGFR at baseline was 61 mL/min/1.73 m<sup>2</sup> and the median proteinuria was 2,600 mg/d. The median follow-up was 5 years with an average annual decline in eGFR of 2.25 mL/min/1.73 m<sup>2</sup>. There was significant inflammation and atrophy seen in the first biopsy, which progressed among those who undertook a 2nd biopsy. Compared to healthy kidney tissue, glomeruli and tubulointerstitium demonstrated increased lymphocyte (CD3+) infiltrates and increased pSTAT1 staining by immunohistochemistry. Increased CD3 (<i>p</i> = 0.001) staining and increased pSTAT1 (<i>p</i> = 0.03) correlated with reduced eGFR levels. In repeat biopsy samples, increasing pSTAT1 staining correlated with loss of eGFR over time (<i>p</i> = 0.02).</p><p><strong>Conclusion: </strong>These findings support the hypothesis that pSTAT1 is activated in IgA nephropathy and may play a role in the progression toward kidney failure.</p>","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"12-18"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/94/gdz-0003-0012.PMC9936761.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9314488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
APOL1 and APOL1-Associated Kidney Disease: A Common Disease, an Unusual Disease Gene - Proceedings of the Henry Shavelle Professorship. APOL1和APOL1相关的肾脏疾病:一种常见疾病,一种不寻常的疾病基因- Henry Shavelle教授会议记录。
Glomerular diseases Pub Date : 2023-01-01 DOI: 10.1159/000529227
Martin R Pollak, David J Friedman
{"title":"APOL1 and APOL1-Associated Kidney Disease: A Common Disease, an Unusual Disease Gene - Proceedings of the Henry Shavelle Professorship.","authors":"Martin R Pollak,&nbsp;David J Friedman","doi":"10.1159/000529227","DOIUrl":"https://doi.org/10.1159/000529227","url":null,"abstract":"<p><strong>Background: </strong>Genetic variants in APOL1 are a major contributor to the increased risk of kidney disease in people of recent African ancestry.</p><p><strong>Summary: </strong>Two alleles in the APOL1 gene, referred to as G1 and G2, confer increased risk of kidney disease under a recessive model of risk inheritance. Disease risk is inherited as a recessive trait: People with genotypes G1/G1, G2/G2, and G1/G2 (i.e., a risk allele from each parent) have increased risk for what we refer to here as APOL1-associated kidney disease. In the USA, about 13% of the self-identified African-American population has a high-risk genotype. As we discuss below, APOL1 is an unusual disease gene. Most studies to date have suggested that the G1 and G2 variants have toxic, gain-of-function effects on the encoded protein.</p><p><strong>Key message: </strong>In this article, we review key concepts critical to understanding APOL1-associated kidney disease, emphasizing ways in which it is highly atypical for a human disease-causing gene.</p>","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"75-87"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/dc/gdz-0003-0075.PMC10126737.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9364661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
An Alport Syndrome Journey: From Powerless to Empowered - A Patient Perspective. 阿尔波特综合症之旅:从无能为力到被授权——一个病人的视角。
Glomerular diseases Pub Date : 2023-01-01 DOI: 10.1159/000529433
Lisa Bonebrake
{"title":"An Alport Syndrome Journey: From Powerless to Empowered - A Patient Perspective.","authors":"Lisa Bonebrake","doi":"10.1159/000529433","DOIUrl":"https://doi.org/10.1159/000529433","url":null,"abstract":"<p><p>As an Alport syndrome patient, caregiver, and executive director of Alport Syndrome Foundation, I am aware of the frequently challenging road in seeking an accurate diagnosis. Our journeys are scattered with misdiagnosis, missed opportunities for accurate diagnosis, counterproductive medications, and overwhelming guilt when our children are diagnosed. We understand that most of our healthcare providers know very little about our disease. Typically, it is incumbent upon us to become empowered through education and connection with our patient community to be sure that our physical and emotional health is well managed.</p>","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"42-46"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f5/35/gdz-2023-0003-0001-529433.PMC9939918.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9313963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Ridge Regression for Functional Form Identification of Continuous Predictors of Clinical Outcomes in Glomerular Disease. 用于肾小球疾病临床结果连续预测因子功能形态识别的岭回归
Glomerular diseases Pub Date : 2023-01-01 DOI: 10.1159/000528847
Jeremy Rubin, Laura Mariani, Abigail Smith, Jarcy Zee
{"title":"Ridge Regression for Functional Form Identification of Continuous Predictors of Clinical Outcomes in Glomerular Disease.","authors":"Jeremy Rubin,&nbsp;Laura Mariani,&nbsp;Abigail Smith,&nbsp;Jarcy Zee","doi":"10.1159/000528847","DOIUrl":"https://doi.org/10.1159/000528847","url":null,"abstract":"<p><strong>Introduction: </strong>Penalized regression models can be used to identify and rank risk factors for poor quality of life or other outcomes. They often assume linear covariate associations, but the true associations may be nonlinear. There is no standard, automated method for determining optimal functional forms (shapes of relationships) between predictors and the outcome in high-dimensional data settings.</p><p><strong>Methods: </strong>We propose a novel algorithm, ridge regression for functional form identification of continuous predictors (RIPR) that models each continuous covariate with linear, quadratic, quartile, and cubic spline basis components in a ridge regression model to capture potential nonlinear relationships between continuous predictors and outcomes. We used a simulation study to test the performance of RIPR compared to standard and spline ridge regression models. Then, we applied RIPR to identify top predictors of Patient-Reported Outcomes Measurement Information System (PROMIS) adult global mental and physical health scores using demographic and clinical characteristics among <i>N</i> = 107 glomerular disease patients enrolled in the Nephrotic Syndrome Study Network (NEPTUNE).</p><p><strong>Results: </strong>RIPR resulted in better predictive accuracy than the standard and spline ridge regression methods in 56-80% of simulation repetitions under a variety of data characteristics. When applied to PROMIS scores in NEPTUNE, RIPR resulted in the lowest error for predicting physical scores, and the second-lowest error for mental scores. Further, RIPR identified hemoglobin quartiles as an important predictor of physical health that was missed by the other models.</p><p><strong>Conclusion: </strong>The RIPR algorithm can capture nonlinear functional forms of predictors that are missed by standard ridge regression models. The top predictors of PROMIS scores vary greatly across methods. RIPR should be considered alongside other machine learning models in the prediction of patient-reported outcomes and other continuous outcomes.</p>","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"47-55"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/0d/gdz-0003-0047.PMC10126734.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9364659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV-Associated Nephropathy in 2022. 2022年hiv相关肾病。
Glomerular diseases Pub Date : 2023-01-01 DOI: 10.1159/000526868
Frederick Berro Rivera, Marie Francesca Mapua Ansay, Jem Marie Golbin, Pia Gabrielle I Alfonso, Gerard Francis E Mangubat, Rajiv Hans Solita Menghrajani, Siena Placino, Marianne Katharina Vicera Taliño, Deogracias Villa De Luna, Nicolo Cabrera, Carlo Nemesio Trinidad, Amir Kazory
{"title":"HIV-Associated Nephropathy in 2022.","authors":"Frederick Berro Rivera,&nbsp;Marie Francesca Mapua Ansay,&nbsp;Jem Marie Golbin,&nbsp;Pia Gabrielle I Alfonso,&nbsp;Gerard Francis E Mangubat,&nbsp;Rajiv Hans Solita Menghrajani,&nbsp;Siena Placino,&nbsp;Marianne Katharina Vicera Taliño,&nbsp;Deogracias Villa De Luna,&nbsp;Nicolo Cabrera,&nbsp;Carlo Nemesio Trinidad,&nbsp;Amir Kazory","doi":"10.1159/000526868","DOIUrl":"https://doi.org/10.1159/000526868","url":null,"abstract":"<p><strong>Background: </strong>HIV-associated nephropathy (HIVAN) is a renal parenchymal disease that occurs exclusively in people living with HIV. It is a serious kidney condition that may possibly lead to end-stage kidney disease, particularly in the HIV-1 seropositive patients.</p><p><strong>Summary: </strong>The African-American population has increased susceptibility to this comorbidity due to a strong association found in the <i>APOL1</i> gene, specifically two missense mutations in the G1 allele and a frameshift deletion in the G2 allele, although a \"second-hit\" event is postulated to have a role in the development of HIVAN. HIVAN presents with proteinuria, particularly in the nephrotic range, as with other kidney diseases. The diagnosis requires biopsy and typically presents with collapsing subtype focal segmental glomerulosclerosis and microcyst formation in the tubulointerstitial region. Gaps still exist in the definitive treatment of HIVAN - concurrent use of antiretroviral therapy and adjunctive management with like renal-angiotensin-aldosterone system inhibitors, steroids, or renal replacement therapy showed benefits.</p><p><strong>Key message: </strong>This study reviews the current understanding of HIVAN including its epidemiology, mechanism of disease, related genetic factors, clinical profile, and pathophysiologic effects of management options for patients.</p>","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1d/ef/gdz-0003-0001.PMC9936764.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9314490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen. 环磷酰胺和类固醇治疗原发性膜性肾病伴严重肾损害的长期安全性、临床和免疫学结果
Glomerular diseases Pub Date : 2023-01-01 DOI: 10.1159/000529605
Omar Ragy, Patrick Hamilton, Anjali Pathi, Adil Abdalla Mohamed Ahmed, Sandip Mitra, Durga A K Kanigicherla
{"title":"Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen.","authors":"Omar Ragy,&nbsp;Patrick Hamilton,&nbsp;Anjali Pathi,&nbsp;Adil Abdalla Mohamed Ahmed,&nbsp;Sandip Mitra,&nbsp;Durga A K Kanigicherla","doi":"10.1159/000529605","DOIUrl":"https://doi.org/10.1159/000529605","url":null,"abstract":"<p><strong>Introduction and aims: </strong>Therapy of primary membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging with limited literature and no clear therapeutic strategies. This is due to the scant evidence of effectiveness and uncertainty around the risk-benefit profile of immunosuppression (ImS) when eGFR is less than 30 mL/min. We aimed to determine long-term clinical outcomes in patients with PMN and severe renal impairment treated with combined cyclophosphamide and steroids.</p><p><strong>Methods: </strong>The study is a single-center retrospective longitudinal cohort study. All patients (between 2004 and 2019) with biopsy confirmed PMN who initiated combination therapy with steroids and cyclophosphamide and had an eGFR of ≤30 mL/min/1.73 m<sup>2</sup> at the time of initiation of therapy were included for analysis. Clinical and laboratory parameters including anti-PLA<sub>2</sub>R-Ab were monitored as per standard clinical guidance. Primary outcome was achievement of partial remission. Secondary outcomes included immunological remission, need for renal replacement therapy, and adverse effects.</p><p><strong>Results: </strong>Eighteen patients with median age of 68 (IQR 58-73) years and 5:1 M:F ratio received the combination therapy when eGFR was ≤30 mL/min/1.73 m<sup>2</sup> (CKD-EPI). At time of ImS, median eGFR and uPCR were 23 (IQR 18-27) mL/min/1.73 m<sup>2</sup> and 8.4 (IQR 6.9-10.7) g/g, respectively. Median follow-up was for 67 (IQR 27-80) months. 16 patients (89%) achieved partial remission and 7 (39%) achieved complete remission. eGFR increased by 7 mL/min/1.73 m<sup>2</sup> (27%) after 1 year of starting ImS treatment and 12 mL/min/1.73 m<sup>2</sup> at end of follow-up. Two patients (11%) developed end-stage renal disease needing renal replacement therapy. 67% achieved both immunological and clinical remission. At the end of the follow-up period, 2 (11%) patients required hospitalization secondary to infections, 4 (22%) patients developed cancer and 4 patients died (22%).</p><p><strong>Conclusion: </strong>Combination therapy with cyclophosphamide and steroids is effective in achieving partial remission and improving renal function in PMN with advanced renal dysfunction. Prospective controlled studies are required to provide further evidence to rationalize treatment and improve outcomes in such patients.</p>","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"88-97"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/e9/gdz-0003-0088.PMC10126738.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9363895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Super-Resolution Microscopy: A Technique to Revolutionize Research and Diagnosis of Glomerulopathies. 超分辨率显微镜:一种革新肾小球疾病研究和诊断的技术。
Glomerular diseases Pub Date : 2023-01-01 DOI: 10.1159/000528713
Florian Siegerist, Vedran Drenic, Thor-Magnus Koppe, Nihal Telli, Nicole Endlich
{"title":"Super-Resolution Microscopy: A Technique to Revolutionize Research and Diagnosis of Glomerulopathies.","authors":"Florian Siegerist,&nbsp;Vedran Drenic,&nbsp;Thor-Magnus Koppe,&nbsp;Nihal Telli,&nbsp;Nicole Endlich","doi":"10.1159/000528713","DOIUrl":"https://doi.org/10.1159/000528713","url":null,"abstract":"<p><strong>Background: </strong>For decades, knowledge about glomerular (patho)physiology has been tightly linked with advances in microscopic imaging technology. For example, the invention of electron microscopy was required to hypothesize about the mode of glomerular filtration barrier function.</p><p><strong>Summary: </strong>Super-resolution techniques, defined as fluorescence microscopy approaches that surpass the optical resolution limit of around 200 nm, have been made available to the scientific community. Several of these different techniques are currently in use in glomerular research. Using three-dimensional structured illumination microscopy, the exact morphology of the podocyte filtration slit can be morphometrically analyzed and quantitatively compared across samples originating from animal models or human biopsies.</p><p><strong>Key messages: </strong>Several quantitative image analysis approaches and their potential influence on glomerular research and diagnostics are discussed. By improving not only optical resolution but also information content and turnaround time, super-resolution microscopy has the potential to expand the diagnosis of glomerular disease. Soon, these approaches could be introduced into glomerular disease diagnosis.</p>","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"19-28"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9314486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Counselling for Kidney Biopsy and Immunosuppression in Glomerulonephritis Using Simulation. 模拟肾小球肾炎患者肾活检和免疫抑制的咨询。
Glomerular diseases Pub Date : 2023-01-01 DOI: 10.1159/000528816
Cynthia Ciwei Lim, Irene Mok, Zhihua Huang, Hui Zhuan Tan, Jason Choo
{"title":"Counselling for Kidney Biopsy and Immunosuppression in Glomerulonephritis Using Simulation.","authors":"Cynthia Ciwei Lim,&nbsp;Irene Mok,&nbsp;Zhihua Huang,&nbsp;Hui Zhuan Tan,&nbsp;Jason Choo","doi":"10.1159/000528816","DOIUrl":"https://doi.org/10.1159/000528816","url":null,"abstract":"not applicable for letter in response to recent publication in this journal","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"29-31"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/df/gdz-0003-0029.PMC9936759.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9328827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoimmunity in Infection-Related Glomerulonephritis. 感染相关性肾小球肾炎的自身免疫。
Glomerular diseases Pub Date : 2023-01-01 DOI: 10.1159/000528712
Hae Yoon Grace Choung, Rickinder Grewal
{"title":"Autoimmunity in Infection-Related Glomerulonephritis.","authors":"Hae Yoon Grace Choung,&nbsp;Rickinder Grewal","doi":"10.1159/000528712","DOIUrl":"https://doi.org/10.1159/000528712","url":null,"abstract":"<p><strong>Introduction: </strong>Autoimmune (AI) reactivity in the setting of infection-related GN (IRGN) is often viewed as an epiphenomenon and is not well described.</p><p><strong>Methods: </strong>We report a cohort of 17 patients with IRGN during a 7-year period that highlights cases with AI reactivity and describes the clinical and pathologic characteristics of IRGN cases associated with AI reactivity.</p><p><strong>Results: </strong>Of the IRGN cases, 76% had clinical evidence of an autoimmune disease (AD) and/or positive AI serologies. Within the IRGN group with AI reactivity, 12 had positive AI serologies (92%) and 10 had AD (77%). 30% had a prior diagnosis of AD, while the remaining 70% did not have a history of AD and were either diagnosed or suspected of having an AD at the time of biopsy. The most common autoantibody detected was anti-nuclear antibody followed by anti-neutrophil cytoplasmic antibodies and autoantibodies associated with antiphospholipid syndrome.</p><p><strong>Conclusion: </strong>The study is not sufficiently powered to determine any significance but demonstrates the frequency with which AI features occur in IRGN and should prompt further future investigation. In summary, our findings suggest AI manifestations are common in IRGN.</p>","PeriodicalId":73177,"journal":{"name":"Glomerular diseases","volume":"3 1","pages":"32-41"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/bf/gdz-0003-0032.PMC9936758.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9328828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信